Pralatrexate
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
| N-(4-{1-[(2,4-diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic acid | |
| Identifiers | |
| CAS number | 146464-95-1 |
| ATC code | none |
| PubChem | 148121 |
| Chemical data | |
| Formula | C23H23N7O5 |
| Mol. mass | 477.47 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Intravenous |
Pralatrexate (rINN), also known as 10-propargyl-10-deazaaminopterin, common name PDX, is a drug candidate being studied for the treatment of cancer. PDX is a folate analog inhibitor of dihydrofolate reductase. As of August 2008[update], it is undergoing Phase II clinical trials for the treatment of Hodgkin and non-Hodgkin lymphoma (including T-cell lymphoma), non-small cell lung cancer (NSCLC), and bladder cancer.
Results in non-small cell lung cancer appear promising.[1]
Accelerated approval and orphan drug status was granted on September 24, 2009 by The US Food and Drug Administration (FDA) for pralatrexate injection (Folotyn, Allos Therapeutics, Inc) as a single agent for the treatment of relapsed or refractory peripheral T-cell lymphoma. (2)
[edit] References
- ^ Krug LM, Azzoli CG, Kris MG, et al. (June 2003). "10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer". Clin. Cancer Res. 9 (6): 2072–8. PMID 12796370. http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=12796370.
(2)http://www.cancer.gov/cancertopics/druginfo/fda-pralatrexate
[edit] External links
- Clinical trials of pralatrexate at ClinicalTrials.gov
- Allos Therapeutics Information on PDX
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
